13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

18 trials found

diseases per page:

Showing 1 to 10 of 18 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05551598 (ClinicalTrials.gov)	November 15, 2022	20/9/2022	Efficacy and Safety of MitoxantroneHydrochloride Liposome Injection in the Treatment of Neuromyeliti ...	A Randomized, Double-blind, Placebo-controlled Phase ? Clinical Study to Evaluate the Efficacy and S ...	Neuromyelitis Optica Spectrum Disorder	Drug: Mitoxantrone Hydrochloride Liposome Injection	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	NULL	Not yet recruiting	18 Years	60 Years	All	45	Phase 2	NULL
2	NCT05496894 (ClinicalTrials.gov)	August 2022	28/7/2022	A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis	A Phase ? Study to Evaluate the Safety and Efficacy of MitoxantroneHydrochloride Liposome Injection ...	Relapsing Multiple Sclerosis	Drug: Mitoxantrone Hydrochloride Liposome Injection	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	NULL	Withdrawn	18 Years	55 Years	All	0	Phase 2	China
3	NCT01627938 (ClinicalTrials.gov)	April 2012	30/5/2012	Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone ...	A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity an ...	Multiple Sclerosis	Drug: Dexrazoxane (DRZ) plus Mitoxantrone (MX);Drug: Placebo plus Mitoxantrone (MX)	PD Dr. Andrew Chan	NULL	Active, not recruiting	18 Years	55 Years	Both	50	Phase 2	Germany
4	NCT02937285 (ClinicalTrials.gov)	November 2010	9/9/2016	National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety ...	National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety ...	Multiple Sclerosis	Drug: Interferon beta 1a;Drug: Mitoxantrone	Rennes University Hospital	NULL	Active, not recruiting	18 Years	50 Years	All	266	Phase 3	France
5	EUCTR2009-010661-23-IT (EUCTR)	30/07/2009	10/01/2011	MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE ...	MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE ...	subjects affected by secondary-progressive Multiple Sclerosis MedDRA version: 9.1;Level: SOC;Classif ...	INN or Proposed INN: Mitoxantrone INN or Proposed INN: Glatiramer acetate	AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI	NULL	Not Recruiting			Female: yes Male: yes			Italy
6	NCT02021825 (ClinicalTrials.gov)	March 2009	3/9/2013	Efficacy and Safety of Mitoxantronein Patients With Refractory Neuromyelitis Optica and Spectrum Dis ...	Efficacy and Safety of Mitoxantronein Patients With Refractory Neuromyelitis Optica and Spectrum Dis ...	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorders	Drug: Mitoxantrone	Xuanwu Hospital, Beijing	NULL	Recruiting	18 Years	55 Years	Both	50	Phase 4	China
7	EUCTR2008-000256-26-GB (EUCTR)	16/02/2009	08/12/2010	An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous inter ...	An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous inter ...	Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclero ...	Trade Name: Mitoxantrone Product Name: Mitoxantrone Product Code: PL 04515/0127 Trade Name: Rebif ® INN o ...	Queen Mary, University of London	NULL	Not Recruiting			Female: yes Male: yes	15	Phase 2	United Kingdom
8	EUCTR2007-001962-34-DE (EUCTR)	12/12/2007	05/11/2007	Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während M ...	Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während M ...	secondary progressive multiple sclerosis	Trade Name: Ralenova INN or Proposed INN: mitoxantrone	University Medical Center Hamburg Eppendorf	NULL	Not Recruiting			Female: yes Male: yes	5		Germany
9	EUCTR2004-001286-17-PT (EUCTR)	08/09/2006	23/03/2006	Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantronein patients under tre ...	Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantronein patients under tre ...	Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity MedDRA ...	Product Name: Mitoxantrone Product Code: N/A	Fundación Española de Esclerosis Múltiple (FEDEM)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		Portugal
10	NCT01142466 (ClinicalTrials.gov)	December 2005	10/6/2010	A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compar ...	Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Wee ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta -1a (Rebif)	Merck KGaA	Gesellschaft für Therapieforschung mbH	Completed	18 Years	60 Years	All	30	Phase 4	NULL

First Previous1 2Next Last